Anthem Biosciences FY26 Revenue Hits ₹2,124 Crores

Anthem Biosciences reported strong FY26 results with consolidated revenue of ₹2,280 crores (18% YoY growth) and PAT of ₹592 crores (31% growth).
The CRDMO business contributed 83% of revenue at ₹1,773 crores (18% growth), while specialty ingredients contributed 17% at ₹352 crores.
Management outlined aggressive expansion plans including Unit 4 capex of ₹1,200 crores over FY27-28 to double custom synthesis capacity.
The company maintains 10 Phase 3 molecules in pipeline and added 4 new commercial molecules in FY26, with biotech funding recovery supporting growth.